Tests that examine the vagina and other organs in the pelvis are used to detect find and diagnose vaginal cancer.
Premature menopause from ovarian damage. Soft tissue or bone necrosis. The proximity of the vagina to the bladder or rectum also limits surgical treatment options and increases short- and long-term surgical complications and functional deficits involving these organs.
For patients with carcinoma of the vagina in its early stages, radiation or surgery or a combination of these treatments are standard treatment. Data from randomized trials are lacking and the choice of therapy is generally determined by institutional experience and the factors listed above.
For patients with stages III and IVA disease, radiation therapy is standard and includes external-beam radiation, alone or with brachytherapy. Regional lymph nodes are included in the radiation portal.
When used alone, external-beam radiation involves a 60 Gy to 70 Gy tumor dose, using shrinking fields, delivered within 6 to 7 weeks.
Intracavitary brachytherapy provides insufficient dose penetration for locally advanced tumors, so interstitial brachytherapy 75 Gy—85 Gy is used if brachytherapy is employed.
In recent years, some investigators have also used concurrent chemotherapy with agents such as cisplatin, bleomycin, mitomycin-C, floxuridine, and vincristine; but this practice has not been proven to improve outcomes. For patients with stage IVB or recurrent disease that cannot be managed with local treatments, current therapy is inadequate.
No established anticancer drugs can be considered of proven clinical benefit, although patients are often treated with regimens used to treat cervical cancer.
Concurrent chemotherapy, using 5-fluorouracil or cisplatin-based therapy, and radiation are sometimes advocated, based solely on extrapolation from cervical cancer management strategies.
Management of the extremely rare vaginal clear cell carcinoma is generally similar to the management of squamous cell carcinoma, though techniques that preserve vaginal and ovarian function are given strong consideration in treatment planning, given the young average age at diagnosis.
Information about ongoing clinical trials is available from the NCI website. Post-therapy Surveillance Similarly to other gynecologic malignancies, the evidence base for surveillance after initial management of vaginal cancer is weak because of a lack of randomized, or even prospective, clinical studies.
Therefore, outside the investigational setting, imaging procedures may be reserved for patients in whom physical examination or symptoms raise clinical suspicion of a recurrence or progression.
Cancer of the cervix, vagina, and vulva. Principles and Practice of Oncology. Definitive radiation therapy for squamous cell carcinoma of the vagina.
Prognostic factors for outcomes and complications for primary squamous cell carcinoma of the vagina treated with radiation. Gynecol Oncol 3: A year experience in the management of primary carcinoma of the vagina: Gynecol Oncol 56 1: Definitive radiotherapy for carcinoma of the vagina: Curr Treat Options Oncol 3 2: Chemoradiation for primary invasive squamous carcinoma of the vagina.
Int J Gynecol Cancer 14 1: Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum. Local therapy in stage I clear cell adenocarcinoma of the vagina. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations.
Am J Obstet Gynecol 6: VAIN, the presence of noninvasive squamous cell atypia, is associated with a high rate of human papillomavirus HPV infection and is thought to have a similar etiology as cervical intraepithelial neoplasia CIN. VAIN 1, 2, and 3 denote involvement of the upper one-third, two-thirds, and more than two-thirds of the epithelial thickness, respectively.
Carcinoma in situ denotes VAIN 3 lesions that involve the full thickness of the epithelium. Because it is associated with other genital neoplasia, and in some cases may be an extension of CIN, the cervix when present and vulva should be carefully evaluated.
Women with VAIN 1 can usually be observed carefully without ablative or surgical treatment because the lesions often regress spontaneously.
The natural history of VAIN is not known with precision because of its rarity, but patients with VAIN 3 are felt to be at substantial risk of progression to invasive cancer and are treated immediately.
The intermediate grade, VAIN 2, is variously managed by careful observation or initial treatment. The treatments listed below have not been compared directly in randomized trials, so their relative efficacy is uncertain. Lesions with hyperkeratosis respond better to excision or laser vaporization than to fluorouracil.Vaginal cancer is a disease in which malignant (cancer) cells form in the vagina.
The vagina is the canal leading from the cervix (the opening of uterus) to the outside of the body.
At birth, a baby passes out of the body through the vagina (also called the birth canal). Vaginal cancer is not common. Vaginal cancer happens when malignant (cancerous) cells form in the vagina. It’s a very uncommon disease. The vagina-- also known as the birth canal -- .
Vaginal Cancer > Vaginal Cancer: Survivorship; Request Permissions. Vaginal Cancer: Survivorship.
Oct 13, · This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of vaginal cancer. It is intended as a resource to inform . A summary of the evidence for this review is shown in Table srmvision.com RCTs of primary hrHPV screening and 4 of cotesting (both hrHPV testing and cytology) compared the use of hrHPV screening for cervical cancer screening with cytology alone for the detection of CIN 3+ and invasive cervical cancer. Short Summary on Vaginal Cancer Essay Vaginal cancer is a rare cancer that occurs in your vagina the, muscular tube that connects your uterus with your outer genitals. Vaginal cancer most commonly occurs in the cells that line the surface of your vagina.
It includes blank treatment summary and survivorship care plan forms. The booklet is available as a PDF, so it is easy to print out. so it is easy to print out. srmvision.com Patient Education Video: View a short video led by an ASCO expert.
Vaginal cancer treatment options include a variety of surgical procedures, topical chemotherapy, radiation therapy, and combination radiation therapy.
Get detailed treatment information for newly diagnosed and recurrent vaginal cancer in this summary . Vaginal cancer is not very common and can be found early with a pap smear.
Learn about risk factors such as HPV and the treatment options available. Summary. Vaginal cancer is a rare type of cancer.
It is more common in women 60 and older. Article: Endometriosis presenting as a vaginal mass. Vaginal Cancer -- see more articles;. Vaginal Cancer and HPV. About nine out of every 10 vaginal cancer cases are linked to human papilloma virus, or HPV, infection. This is the most common STI, or sexually transmitted infection.